A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Trial Profile

A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 23 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 09 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top